# Junta clínica — PT-pseudo_0615b2bd8504 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_0615b2bd8504",
  "pid": "PT-pseudo_0615b2bd8504",
  "task": 1,
  "psa": 160.0,
  "age": 63,
  "months": 1,
  "pirads": "5",
  "psad": 2.635,
  "psav": 35.73,
  "psap": 115.9,
  "vol": 60.71,
  "dre": "Abnormal",
  "bx": "Positive",
  "cspca": 0.95889634,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 160 ng/mL. PI-RADS 5. PSAD 2.63. Prostate volume 61 mL. DRE abnormal. csPCa 0.96.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "93 kg",
    "height": "191 cm",
    "bmi": "25.5",
    "bp": "140/81 mmHg",
    "hr": "48 bpm",
    "smoking": "Current smoker (20 pack-yr)",
    "last_dental": "2 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "26 Jan 2025",
  "enc_ref": "Dr. C. Peters (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent elevation in PSA levels alongside a history of biopsy-confirmed prostate adenocarcinoma warrants clinical reassessment."
    },
    {
      "s": "History",
      "t": "Now aged 63-year-old, the individual works as a retired bank clerk and Lives in ground-floor apartment with partner. Following an initial PSA measurement of 55.0 ng/mL in late 2022, a prior biopsy bucket \"Positive\" was documented. He maintains a Married status and engages in light resistance training twice weekly, complemented by a moderate alcohol intake of 14 units per week. Current smoker (20 pack-yr) status is noted, though he explicitly denies haematuria, pelvic discomfort, or lower urinary tract symptoms exceeding a baseline IPSS of 10. Past medical reviews include a routine hearing evaluation, an orthopaedic check for stable knee osteoarthritis, and a memory clinic assessment revealing intact cognition. He has never utilized 5-alpha-reductase inhibitors. General health remains excellent with an ECOG performance status of 0. Comorbidities: none. Active medication: None."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm and irregular nodule palpable in the left posterior peripheral zone; mobility: fixed; asymmetry: pronounced enlargement with right lobe induration but no distinct discrete masses; overall classification: cT3a. Abnormal DRE confirmed. Vital signs record a blood pressure of 140/81 mmHg and a resting heart rate of 48 bpm. General survey shows no palpable lymphadenopathy or hepatosplenomegaly."
    }
  ],
  "occupation": "retired bank clerk",
  "marital": "Married",
  "living": "Lives in ground-floor apartment with partner",
  "next_of_kin": "Sibling (brother)",
  "recent_other": [
    "Audiology — hearing test",
    "Orthopaedic outpatient — knee follow-up",
    "Memory clinic — baseline screening"
  ],
  "alcohol": "14 units / week",
  "exercise": "Light weight-training at home, 2x/week",
  "ipss": "IPSS score: 10/35 (moderate LUTS)",
  "admin": "Patient self-employed; flexible appointment slots requested.",
  "mri_hospital": "Amsterdam UMC (location AMC)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_0615b2bd8504
Task: 1

Encounter: Urology - outpatient on 26 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 160.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 2.635 ng/mL²
  - PSA velocity: 35.73 ng/mL/yr
  - Prior PSA: 115.9 ng/mL
  - Prostate volume: 60.71 mL
  - Months since last PSA: 1
  - DRE findings: Abnormal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.95889634 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 160 ng/mL. PI-RADS 5. PSAD 2.63. Prostate volume 61 mL. DRE abnormal. csPCa 0.96.

Vitals: weight 93 kg, height 191 cm, BMI 25.5, BP 140/81 mmHg, HR 48 bpm. Smoking: Current smoker (20 pack-yr).

Chief complaint: Persistent elevation in PSA levels alongside a history of biopsy-confirmed prostate adenocarcinoma warrants clinical reassessment.

History: Now aged 63-year-old, the individual works as a retired bank clerk and Lives in ground-floor apartment with partner. Following an initial PSA measurement of 55.0 ng/mL in late 2022, a prior biopsy bucket "Positive" was documented. He maintains a Married status and engages in light resistance training twice weekly, complemented by a moderate alcohol intake of 14 units per week. Current smoker (20 pack-yr) status is noted, though he explicitly denies haematuria, pelvic discomfort, or lower urinary tract symptoms exceeding a baseline IPSS of 10. Past medical reviews include a routine hearing evaluation, an orthopaedic check for stable knee osteoarthritis, and a memory clinic assessment revealing intact cognition. He has never utilized 5-alpha-reductase inhibitors. General health remains excellent with an ECOG performance status of 0. Comorbidities: none. Active medication: None.

Physical examination: DRE — texture: firm and irregular nodule palpable in the left posterior peripheral zone; mobility: fixed; asymmetry: pronounced enlargement with right lobe induration but no distinct discrete masses; overall classification: cT3a. Abnormal DRE confirmed. Vital signs record a blood pressure of 140/81 mmHg and a resting heart rate of 48 bpm. General survey shows no palpable lymphadenopathy or hepatosplenomegaly.

Patient info: retired bank clerk; Married; Lives in ground-floor apartment with partner.
Next of kin: Sibling (brother).

Lifestyle: alcohol 14 units / week; exercise Light weight-training at home, 2x/week; IPSS score: 10/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test; Orthopaedic outpatient — knee follow-up; Memory clinic — baseline screening.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.33
  uncertainty  +/- 0.13 (95% CI 0.07-0.60); among patients it cannot tell apart the outcome was 0.92 of 1.00 mixed
  confidence   MODERATE — in this tier it was right 80% of the time over 20 labelled cases

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. I have no answer for him, and that is the finding.

The criterion here is that the visible panel does not determine this decision: the man already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. Measured on the 49 labelled cases in this
situation: no structured variable separates the two answers — PSA is rising in all 49 — the
split is 26 defer / 23 biopsy, and every rule fitted on one half failed on the other.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle
this man and the retrieved documents have to.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline discusses using PI-RADS thresholds to guide the decision to perform a biopsy. It states, "a PI-RADS threshold of $\\ge 3$ is used to trigger biopsy [135, 226, 264, 375], at the cost of missing a small number of mainly ISUP GG 2 cancers, especially in biopsy-naïve patients or in highly selected populations with high prevalence of csPCa (in which the MRI NPV decreases) [372, 472]."

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of "NO BIOPSY" is blind to the fact that the patient has a PI-RADS 5 lesion and a very high PSA (160.0 ng/mL). The guideline suggests that a PI-RADS $\\ge 3$ triggers biopsy, and the classifier's bid does not account for the high-risk features present in this case.

WHAT WE STILL NEED
The mpMRI prose - the mpMRI prose indicates a PI-RADS 5 score, which is a high-risk finding that aligns with the guideline suggesting a biopsy trigger.
The PSA trend - the PSA velocity is $35.73 \text{ ng/mL/yr}$, which is a significant rate of increase, which is a factor that the guideline suggests should be considered in the decision.
The previous notes - the notes state the prior biopsy was "Positive," which is a fact that the guideline makes decisive regarding the need for further investigation.
The laboratory results - the PSA density is $2.635 \text{ ng/mL}^2$, which is a factor that the guideline uses in risk-adapted matrices to guide the decision.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on whether the high-risk imaging features and the significant PSA velocity outweigh the prior positive biopsy result.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine the mpMRI prose, including lesion characteristics and comparison to prior studies.
  psa_trend (get_psa_trend) -> Determine the PSA trend details beyond the headline value.
  previous_notes (get_previous_notes) -> Confirm the details of the prior biopsy result and any surveillance plan.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What does the mpMRI prose indicate regarding the lesion size, zone, and extraprostatic extension?
  Q2. What does the PSA trend indicate regarding the rate of PSA increase beyond the headline value?

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose indicates a PI-RADS 5 lesion in the left peripheral zone spanning roughly 35 mm, with suspected extracapsular extension on the left posterolateral margin.
psa_trend
The PSA trend indicates a significant rate of increase, with a value of $35.73 \text{ ng/mL/yr}$ between the measurement in April 2024 ($12.0 \text{ ng/mL}$) and the current measurement of $160.0 \text{ ng/mL}$ in January 2025.
previous_notes
The previous notes confirm that the prior biopsy result was "Positive" (Gleason 3+4 pathology) documented on "31 May 2024".

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator did not specifically ask for them, and the key findings regarding PSA density were already incorporated into the Expert-EAU's reasoning based on the panel data.

WHAT THIS SUPPORTS
FOR sampling this patient now
The mpMRI prose indicates a PI-RADS 5 lesion with suspected extracapsular extension.
The PSA trend indicates a significant rate of increase of $35.73 \text{ ng/mL/yr}$.
AGAINST sampling this patient now
The previous notes confirm the patient already has a tissue diagnosis from a prior positive biopsy.

WHERE THIS LEANS
The high-risk imaging features and the significant PSA velocity strongly support proceeding with further investigation, despite the prior diagnosis.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar successfully answered Q1 and Q2 by retrieving the `radiology_report` and `psa_trend`, which provided the necessary details on the lesion characteristics and the rate of PSA increase.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the Expert-EAU's reasoning and supports the conclusion that biopsy is warranted, as the high-risk imaging features (PI-RADS 5 with suspected extracapsular extension) and the significant PSA velocity are factors the guideline suggests should be considered.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the mpMRI prose indicate regarding the lesion size, zone, and extraprostatic extension? Answered by the registrar via the `radiology_report`, indicating a PI-RADS 5 lesion spanning 35 mm with suspected extracapsular extension.
Q2. What does the PSA trend indicate regarding the rate of PSA increase beyond the headline value? Answered by the registrar via the `psa_trend`, indicating a significant rate of increase of $35.73 \text{ ng/mL/yr}$.

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables are the PI-RADS 5 lesion with suspected extracapsular extension, which signifies high local risk, and the significant PSA velocity of $35.73 \text{ ng/mL/yr}$, which indicates aggressive disease progression. The prior positive biopsy is the variable the room has been leaning on that the guideline does not explicitly support as a reason to defer, as the high-risk features override this history.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy to further characterize the high-risk imaging findings and the rapid PSA progression. This should be done firmly.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

Despite the prior positive biopsy, the high-risk imaging features, specifically the PI-RADS 5 lesion with suspected extracapsular extension, and the significant PSA velocity of 35.73 ng/mL/yr strongly support proceeding with a biopsy. The retrieved documentation confirmed the high-risk imaging and rapid progression, which overrides the prior diagnosis for the purpose of further characterization.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=important, cspca=noted, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
